Autolus Therapeutics plc (AUTL)
| Market Cap | 436.47M +14.7% |
| Revenue (ttm) | 75.39M +644.9% |
| Net Income | -287.53M |
| EPS | -1.08 |
| Shares Out | 266.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,379,488 |
| Open | 1.600 |
| Previous Close | 1.570 |
| Day's Range | 1.575 - 1.670 |
| 52-Week Range | 1.150 - 2.700 |
| Beta | 1.93 |
| Analysts | Strong Buy |
| Price Target | 8.50 (+418.29%) |
| Earnings Date | May 14, 2026 |
About AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in ph... [Read more]
Financial Performance
In 2025, Autolus Therapeutics's revenue was $75.39 million, an increase of 644.94% compared to the previous year's $10.12 million. Losses were -$287.53 million, 30.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for AUTL stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 418.29% from the latest price.
News
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026
LONDON and GAITHERSBURG, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-gener...
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
Initiative focused on driving gross profit margin and path to profitability for the ALL business Company will reduce headcount by approximately 13% while doubling manufacturing of products for commerc...
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON and GAITHERSBURG, Md., April 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gen...
Autolus Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
AUCATZYL (obe-cel) demonstrates strong efficacy and safety in relapsed/refractory ALL, with expanding U.S. and U.K. market presence and robust real-world results. Ongoing trials target broader patient groups, including frontline and pediatric populations, while margin improvements and scalable manufacturing support future growth.
Autolus Therapeutics Transcript: Status update
Obe-cel CAR T-cell therapy demonstrates high efficacy and a favorable safety profile in both clinical trials and real-world settings for adult and pediatric ALL, enabling broader patient access and reducing reliance on transplantation. Ongoing studies aim to expand its use to frontline consolidation, with promising early results and increasing adoption across treatment centers.
Autolus Therapeutics to Participate in Upcoming Investor Conferences
LONDON and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gen...
Autolus Therapeutics Earnings Call Transcript: Q4 2025
AUCATZYL generated $74.3M in 2025 revenue with strong real-world efficacy and safety, and 2026 guidance targets $120–$135M with positive gross margins. Expansion into new indications and markets is underway, with cash runway into Q4 2027.
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
LONDON and GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gen...
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026
LONDON and GAITHERSBURG, Md., March 16, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-gen...
Autolus Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Obe-cel achieved rapid market leadership in relapsed/refractory adult acute leukemia, with strong safety and efficacy data supporting expansion into pediatric, lupus nephritis, and progressive MS indications. Manufacturing optimization and broad U.S. center reach underpin growth, with pivotal study milestones expected through 2028.
Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026
Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025 Autolus anticipa...
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform
SOUTH SAN FRANCISCO, Calif. and LONDON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering...
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform
SOUTH SAN FRANCISCO, Calif. & LONDON--(BUSINESS WIRE)--Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation pr...
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
Autolus presented preliminary data from the Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) at ASH 2025.
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune e...
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors
LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering ne...
Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?
The U.K.'s National Institute for Health and Care Excellence (NICE) published on Tuesday draft guidance recommending Autolus Therapeutics plc's (NASDAQ: AUTL) Aucatzyl (obecabtagene autoleucel, or obe...
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹
LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programm...
Autolus Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Aucatzyl (OBE-cel) is now active in over 60 centers with strong sales and robust clinical data, including a 77% remission rate and durable responses. Expansion efforts target new indications in pediatrics and autoimmune diseases, while operational efficiency and market share growth remain key priorities.
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
LONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering ne...
Autolus Therapeutics Earnings Call Transcript: Q3 2025
AUCATZYL achieved U.S. market leadership in relapsed/refractory B-ALL with $21.1M Q3 revenue and broad access, while pipeline expansion and operational optimization are underway. Cash reserves of $367.4M support ongoing pivotal trials, with margin improvements expected as volumes rise.
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of target Clinical execution and data genera...
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025
LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering ne...
Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
LONDON & GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next...
Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025
Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Pha...